Gilead Sciences Inc (GILD):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Gilead Sciences Inc (GILD) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7322
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:81
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Gilead Sciences Inc (Gilead) is a research-based biopharmaceutical company. It focuses on the discovery, development and commercialization of medicines for the treatment of cardiovascular, hematological and respiratory diseases, inflammation, liver diseases, cancer and human immunodeficiency virus (HIV) infection. The company also has a wide range of pipeline products in different stages of development. Gilead strives to develop products that offer improved methods of delivery, enhanced resistance profile, minimized side effects and greater efficiency. Gilead sells its products through marketing subsidiaries and distributors in Europe, the Americas, Asia-Pacific, the Middle East and Africa. The company has partnerships with universities, medical research institutions and global pharmaceutical leaders to develop new drugs. Gilead is headquartered in Foster City, California, the US.

Gilead Sciences Inc (GILD) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Gilead Sciences Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Gilead Sciences Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Gilead Sciences Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Gilead Sciences Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 9
Gilead Sciences Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Gilead Sciences Inc, Medical Equipment, Deal Details 11
Partnerships 11
Kite Pharma Enters into Agreement with Vitruvian Networks 11
Debt Offering 12
Gilead Sciences Raises USD750 Million in Public Offering of Notes Due 2018 12
Gilead Sciences Raises USD1 Billion in Public Offering of 1.85% Notes Due 2019 14
Gilead Sciences Raises USD750 Million in Public Offering of Notes Due 2019 16
Gilead Sciences Raises USD500 Million in Public Offering of Notes Due 2019 18
Gilead Sciences Raises USD1.25 Billion in Public Offering of 2.95% Notes Due 2027 20
Gilead Sciences Raises USD0.5 Billion in Public Offering of 1.95% Notes Due 2022 22
Gilead Sciences Raises USD1.75 Billion in Public Offering of 4.15% Notes Due 2047 24
Gilead Sciences Raises USD0.75 Billion in Public Offering of 4% Notes Due 2036 26
Gilead Sciences Raises USD0.75 Billion in Public Offering of 2.5% Notes Due 2023 28
Gilead Sciences Raises USD2.25 Billion in Public Offering of 4.75% Notes Due 2046 30
Gilead Sciences Raises USD1 Billion in Public Offering of 1.85% Notes Due 2018 32
Gilead Sciences Raises USD1 Billion in Public Offering of 3.25% Notes Due 2022 34
Gilead Sciences Raises USD2 Billion in Public Offering of 2.55% Notes Due 2020 36
Gilead Sciences Raises USD2.75 Billion in Public Offering of 3.65% Notes Due 2026 38
Gilead Sciences Raises USD1 Billion in Public Offering of 4.6% Notes Due 2035 40
Gilead Sciences Inc – Key Competitors 42
Gilead Sciences Inc – Key Employees 43
Gilead Sciences Inc – Locations And Subsidiaries 45
Head Office 45
Other Locations & Subsidiaries 45
Joint Venture 49
Recent Developments 50
Strategy And Business Planning 50
May 15, 2018: Kite Announces New Worldwide Facilities and Expanded Collaboration With National Cancer Institute to Support Cell Therapy Pipeline 50
Financial Announcements 51
Jul 25, 2018: Gilead Sciences Announces Second Quarter 2018 Financial Results 51
May 01, 2018: Gilead Sciences Announces First Quarter 2018 Financial Results 54
Feb 06, 2018: Gilead Sciences Announces Fourth Quarter and Full Year 2017 Financial Results 56
Oct 26, 2017: Gilead Sciences Announces Third Quarter 2017 Financial Results 59
Jul 26, 2017: Gilead Sciences Announces Second Quarter 2017 Financial Results 61
May 02, 2017: Gilead Sciences Announces First Quarter 2017 Financial Results 63
Feb 07, 2017: Gilead Sciences Announces Fourth Quarter and Full Year 2016 Financial Results 65
Corporate Communications 67
Aug 28, 2018: Gilead Sciences names Laura Hamill as executive vice president, worldwide commercial operations 67
Aug 14, 2018: Gilead Sciences Announces Executive Promotions 68
Jul 25, 2018: Gilead Sciences announces CEO John F. Milligan to step down 69
Jun 11, 2018: Gilead Sciences’ Chief Scientific Officer John McHutchison Appointed Officer of the Order of Australia 70
Jun 04, 2018: Gilead Sciences Announces Leadership Changes in Corporate Development and Strategy 71
May 15, 2018: Kite Announces New Worldwide Facilities and Expanded Collaboration With National Cancer Institute to Support Cell Therapy Pipeline 72
May 09, 2018: Harish Manwani Joins Gilead Sciences’ Board of Directors 73
Mar 12, 2018: Gilead Sciences Announces Senior Management Changes 74
Feb 22, 2018: Gilead Sciences Announces Senior Management Change 75
Feb 01, 2018: Gilead Sciences Appoints Jacqueline K. Barton As Board of Directors 76
Dec 14, 2017: Gilead Sciences Announces That John C. Martin, PhD Will Transition From Executive Chairman to Chairman of the Board of Directors 77
Oct 17, 2017: Gilead Sciences Announces Promotion of Alessandro Riva to Executive Vice President, Oncology Therapeutics 78
Sep 27, 2017: Kevin Young CBE, Gilead’s Chief Operating Officer, to Retire 79
Jan 03, 2017: Alessandro Riva, MD, to Join Gilead as Senior Vice President, Hematology and Oncology Therapeutic Area Head 80
Appendix 81
Methodology 81
About GlobalData 81
Contact Us 81
Disclaimer 81

List of Tables
Gilead Sciences Inc, Medical Equipment, Key Facts, 2017 2
Gilead Sciences Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Gilead Sciences Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Gilead Sciences Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Gilead Sciences Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Gilead Sciences Inc, Deals By Market, 2012 to YTD 2018 9
Gilead Sciences Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Kite Pharma Enters into Agreement with Vitruvian Networks 11
Gilead Sciences Raises USD750 Million in Public Offering of Notes Due 2018 12
Gilead Sciences Raises USD1 Billion in Public Offering of 1.85% Notes Due 2019 14
Gilead Sciences Raises USD750 Million in Public Offering of Notes Due 2019 16
Gilead Sciences Raises USD500 Million in Public Offering of Notes Due 2019 18
Gilead Sciences Raises USD1.25 Billion in Public Offering of 2.95% Notes Due 2027 20
Gilead Sciences Raises USD0.5 Billion in Public Offering of 1.95% Notes Due 2022 22
Gilead Sciences Raises USD1.75 Billion in Public Offering of 4.15% Notes Due 2047 24
Gilead Sciences Raises USD0.75 Billion in Public Offering of 4% Notes Due 2036 26
Gilead Sciences Raises USD0.75 Billion in Public Offering of 2.5% Notes Due 2023 28
Gilead Sciences Raises USD2.25 Billion in Public Offering of 4.75% Notes Due 2046 30
Gilead Sciences Raises USD1 Billion in Public Offering of 1.85% Notes Due 2018 32
Gilead Sciences Raises USD1 Billion in Public Offering of 3.25% Notes Due 2022 34
Gilead Sciences Raises USD2 Billion in Public Offering of 2.55% Notes Due 2020 36
Gilead Sciences Raises USD2.75 Billion in Public Offering of 3.65% Notes Due 2026 38
Gilead Sciences Raises USD1 Billion in Public Offering of 4.6% Notes Due 2035 40
Gilead Sciences Inc, Key Competitors 42
Gilead Sciences Inc, Key Employees 43
Gilead Sciences Inc, Other Locations 45
Gilead Sciences Inc, Subsidiaries 45
Gilead Sciences Inc, Joint Venture 49

List of Figures
Gilead Sciences Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Gilead Sciences Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Gilead Sciences Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Gilead Sciences Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Gilead Sciences Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Gilead Sciences Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 7
Gilead Sciences Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Gilead Sciences Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 9

★海外企業調査レポート[Gilead Sciences Inc (GILD):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • MarketSource Inc:企業の戦略的SWOT分析
    MarketSource Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • AusNet Services Ltd (AST):企業の財務・戦略的SWOT分析
    AusNet Services Ltd (AST) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Eucatex SA Industria e Comercio:企業の戦略・SWOT・財務情報
    Eucatex SA Industria e Comercio - Strategy, SWOT and Corporate Finance Report Summary Eucatex SA Industria e Comercio - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Valneva SE (VLA):企業の財務・戦略的SWOT分析
    Valneva SE (VLA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Mylan NV (MYL)-医療機器分野:企業M&A・提携分析
    Summary Mylan NV (Mylan) is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generics and branded medicines and consumer healthcare products. It offers pharmaceutical products in multiple forms across therapeutic categories such as respiratory and allergy, ca …
  • GfK SE:企業の戦略・SWOT・財務分析
    GfK SE - Strategy, SWOT and Corporate Finance Report Summary GfK SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • Wartsila Corp (WRT1V):電力:M&Aディール及び事業提携情報
    Summary Wartsila Corp (Wartsila) is a mechanical or industrial engineering company. It offers smart technologies and complete lifecycle solutions. Through sustainable innovation, total efficiency, and data analytics, the company harnesses the environmental and economic performance of the vessels and …
  • Future Fund:企業の戦略的SWOT分析
    Future Fund - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Ck Hutchison Holdings Ltd:企業の戦略・SWOT・財務分析
    Ck Hutchison Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Ck Hutchison Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Talwalkars Better Value Fitness Ltd (TALWALKARS):企業の財務・戦略的SWOT分析
    Talwalkars Better Value Fitness Ltd (TALWALKARS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key s …
  • Industrial and Commercial Bank of China Ltd:企業のM&A・事業提携・投資動向
    Industrial and Commercial Bank of China Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Industrial and Commercial Bank of China Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, det …
  • Vienna Insurance Group AG:企業のM&A・事業提携・投資動向
    Vienna Insurance Group AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Vienna Insurance Group AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisi …
  • Adana Cimento Sanayii Tas
    Adana Cimento Sanayii Tas - Strategy, SWOT and Corporate Finance Report Summary Adana Cimento Sanayii Tas - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Royal Caribbean Cruises Ltd.:戦略・SWOT・企業財務分析
    Royal Caribbean Cruises Ltd. - Strategy, SWOT and Corporate Finance Report Summary Royal Caribbean Cruises Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Li & Fung Limited:企業の戦略・SWOT・財務情報
    Li & Fung Limited - Strategy, SWOT and Corporate Finance Report Summary Li & Fung Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • WESCO International, Inc.:企業の戦略・SWOT・財務情報
    WESCO International, Inc. - Strategy, SWOT and Corporate Finance Report Summary WESCO International, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Adhera Therapeutics (MRNA):製薬・医療:M&Aディール及び事業提携情報
    Summary Adhera Therapeutics (Adhera) is a nucleic acid-based drug discovery and development company that focuses on rare diseases. It focuses on treating the intersection of arthritis, hypertension, pain, and cancer using combination therapies of already approved drugs. The company is developing and …
  • EndoStim Inc-医療機器分野:企業M&A・提携分析
    Summary EndoStim Inc (EndoStim) is a medical device company that offers therapeutic solutions. The company develops and commercializes a neurostimulation system for the treatment of severe gastroesophageal reflux disease. It concentrates on the treatment of gastroesophageal reflux disease through el …
  • G-III Apparel Group, Ltd.:企業の戦略・SWOT・財務分析
    G-III Apparel Group, Ltd. - Strategy, SWOT and Corporate Finance Report Summary G-III Apparel Group, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Novaliq GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary Novaliq GmbH (Novaliq) is a drug delivery company that develops pharmaceutical formulations. The company develops dermatological products, novel ophthalmic, and solutions for organ preservation based on the physicochemical properties of semifluorinated alkanes. It offers NovaTears a preserva …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆